KUROS BIOSCIENCES AG Schlieren (Zurich), Switzerland, April 30, 2018
Kuros Biosciences Reports Full-Year 2017 Results
Kuros Biosciences reported today its Full-Year 2017 Results, and the publication of its annual report.
Financial highlights
- CHF 17.0 million cash at year-end
- CHF 16.9 million equity raise in June 2017
- Standby equity facility established in November 2017 to increase financial flexibility
Operational highlights
- Successful completion of merger with Xpand Biotechnology creating a leader in orthobiologics
- FDA approvals for MagnetOs Granules & Putty
- Prepared for U.S. launch of MagnetOs by end of June 2018
- Clinical development of Fibrin-PTH for spinal fusion on track
2017 has been a transformative year for Kuros Biosciences, which successfully transitioned into a full-fledged orthobiologics company with scientific, clinical, and commercial excellence in bone regeneration. MagnetOs Granules and MagnetOs Putty have been cleared by the U.S. Food and Drug Administration, and the Company is gearing up for their U.S. commercial launch in 2018.
Joost de Bruijn, Chief Executive Officer, said: "During 2017 we successfully set Kuros on a new course - one that is focused on cutting-edge orthobiologics, an important commercial opportunity. Our international team has responded with verve to our ongoing commercial transition, embracing their new challenges. As a result, we are well-positioned to execute on the commercial roll-out plan for MagnetOs in the U.S. and drive forward our exciting clinical program with Fibrin-PTH in spinal fusion, which represents a huge opportunity."
Financial position
Cash and cash equivalents (including financial assets and trade and other receivables) as per December 31, 2017, amounted to CHF 17.0 million, compared with CHF 13.0 million as per December 31, 2016. The increase is mainly due to capital increases which off-set net operating cash. In 2017, Kuros received a milestone payment of TCHF 534 (TCHF 997 in 2016) from a collaboration partner. Operating costs for 2017 amounted to CHF 16.8 million, compared with CHF 22.4 million in the previous year. Research and development expenses decreases from CHF 7.9 million in 2016 to CHF 4.5 million in 2017. General and administrative expenses decreased from CHF 17.1 million in 2016 to CHF 15.2 million in 2017.
During 2017, Kuros raised CHF 16.9 million in equity, and put a CHF 30 million equity financing facility in place to provide the Company with more financial flexibility.
Key figures | 2017 | 2016 | |
In TCHF, IFRS | |||
Revenue | 534 | 1,061 | |
Research and development | (4,470) | (7,909) | |
General and administration | (15,242) | (17,070) | |
Other income | 2,935 | 2,572 | |
Net operating costs | (16,777) | (22,407) | |
Operating income/(loss) | (16,243) | (21,346) | |
Net financial income/(loss) | (350) | 1,069 | |
Net income/(loss) | (16,484) | (19,744) | |
Net income/(loss) per share (in CHF) | (2.32) | (3.95) | |
Cash and cash equivalents, financial assets and trade and other receivables | 17,024 | 13,034 |
Outlook
In 2018, the Company aims to capitalize on the restructuring as it executes on its renewed focus on orthobiologics. This includes setting-up a U.S. commercial infrastructure to support the U.S. launch of MagnetOs, as well as the preparation of a Phase 2 clinical study for our drug-based Fibrin-PTH product candidate KUR-113 for spinal indications.
Annual report
The annual report of Kuros Biosciences is available online at
www.kuros.ch/investors/reports-presentations.html.
| Provider | Channel | Contact | ||
|---|---|---|---|---|
|
Tensid EQS Ltd., Switzerland www.tensid.ch |
newsbox.ch www.newsbox.ch |
Provider/Channel related enquiries marco@tensid.ch +41 41 763 00 50 |
